A forty-eight (48) week optional open-label extension period (Open- Label Period), which may be extended by 12-week increments until discontinued by the Sponsor for participants that have completed protocol CNMAu8.205.
This is an optional open-label extension to participants that have completed the clinical trial CNMAu8.205.